On May 15, 2026, the U.S. Food and Drug Administration (FDA) approved fam-trastuzumab deruxtecan-nxki (Enhertu®, T-DXd), the HER2-targeted antibody-drug conjugate (ADC) co-developed by Daiichi Sankyo and AstraZeneca, for two new indications in HER2-positive early-stage breast cancer (Stage II/III): (1) neoadjuvant T-DXd followed by taxane plus trastuzumab and pertuzumab; and (2) adjuvant T-DXd for patients with residual invasive disease after neoadjuvant therapy. This approval moves T-DXd — historically a metastatic-disease therapy — into the curative-intent early-stage setting, with potential to rewrite the HER2-positive early breast cancer treatment paradigm. This article summarizes the pivotal DESTINY-Breast05 / -Breast11 trials, efficacy and safety outcomes, and regulatory and clinical implications.
Target Patient Population
- Adults with HER2-positive (IHC 3+ or IHC 2+/ISH-positive) breast cancer
- Stage II or III (locally advanced included)
- Indication 1 (neoadjuvant): Untreated HER2+ early breast cancer; T-DXd monotherapy followed by taxane + trastuzumab + pertuzumab
- Indication 2 (adjuvant): Following neoadjuvant therapy with residual invasive disease at surgery
- Both indications carry tightly defined patient population and treatment-stage definitions
Pivotal Trial Overview
The approval is supported by the DESTINY-Breast trial program in HER2-positive early breast cancer, principally DESTINY-Breast05 (NCT04622319; high-risk adjuvant setting) and DESTINY-Breast11 (NCT05113251; neoadjuvant setting).
| Item | DESTINY-Breast05 | DESTINY-Breast11 |
|---|---|---|
| Trial ID | NCT04622319 | NCT05113251 |
| Design | Randomized, open-label, Phase 3 | Randomized, open-label, Phase 3 |
| N | ~1,600 | ~900 |
| Population | Residual invasive disease after neoadjuvant therapy | Untreated HER2+ Stage II/III |
| Intervention | T-DXd × 14 cycles | T-DXd → taxane + H+P |
| Comparator | T-DM1 × 14 cycles (KATHERINE regimen) | Taxane + H+P → A regimen |
| Primary endpoint | Invasive disease-free survival (iDFS) | Pathologic complete response (pCR) |
T-DXd is an antibody-drug conjugate composed of trastuzumab covalently linked to the topoisomerase I inhibitor payload DXd (deruxtecan), with a drug-to-antibody ratio of approximately 8. After internalization into HER2-expressing cells and lysosomal cleavage of the linker, DXd is released. The payload also diffuses to adjacent HER2-low or -negative cells (the so-called “bystander effect”), giving the molecule activity even in heterogeneously HER2-expressing tumors.
Standard HER2+ early breast cancer care has historically been taxane + H+P + AC neoadjuvantly, followed by adjuvant T-DM1 for residual invasive disease (the KATHERINE regimen). The new approvals advance two changes simultaneously: deeper pCR with T-DXd-led neoadjuvant therapy, and improved iDFS by using T-DXd instead of T-DM1 in the adjuvant setting for residual disease.
Key Efficacy Results
| Trial | Primary endpoint | Result |
|---|---|---|
| DESTINY-Breast11 (neoadjuvant) | pCR rate (T-DXd → taxane + H+P vs standard) | T-DXd arm pCR ~65–70% (significantly higher than ~50% in control) |
| DESTINY-Breast05 (adjuvant after residual) | iDFS (T-DXd vs T-DM1) | iDFS HR ~0.55 (p < 0.001, statistically significant) |
DESTINY-Breast11 demonstrated that a T-DXd-led neoadjuvant regimen significantly increased pCR rate versus the current standard. pCR is a long-validated surrogate for long-term outcome in HER2+ early breast cancer, and the T-DXd → taxane + H+P regimen has a more favorable neurotoxicity profile than anthracycline-containing regimens — a meaningful patient-experience improvement.
DESTINY-Breast05 showed that replacing adjuvant T-DM1 with T-DXd in patients with residual invasive disease after neoadjuvant therapy improved iDFS with a hazard ratio of approximately 0.55 — corresponding to roughly a 45% reduction in the relative risk of disease recurrence or death. This is one of the largest treatment-effect improvements in early breast cancer adjuvant therapy in the past five years. Together, the two trials provide a substantial new framework for HER2-positive early breast cancer.
Safety Profile
The safety profile is consistent with prior T-DXd experience in metastatic disease. Interstitial lung disease / pneumonitis (ILD) remains the most important toxicity to manage.
| Adverse Event | All grades | Grade ≥3 |
|---|---|---|
| Nausea | ~75% | ~8% |
| Fatigue | ~60% | ~7% |
| Neutropenia | ~45% | ~20% |
| Alopecia | ~40% | — |
| Vomiting | ~35% | ~3% |
| Anemia | ~30% | ~8% |
| Interstitial lung disease / pneumonitis (ILD) | ~10–15% | ~2–3% (including Grade 5) |
| LVEF decrease | ~5% | <1% |
The product label carries Boxed Warnings for ILD/pneumonitis and embryo-fetal toxicity. In the curative-intent early-stage setting, the threshold for ILD tolerance is lower than in the metastatic setting. Baseline pulmonary function assessment, vigilant monitoring for cough, dyspnea, and oxygen desaturation, scheduled imaging (high-resolution CT before initiation and periodically during treatment), dose interruption and corticosteroid initiation at Grade 1 ILD, and permanent discontinuation at Grade ≥2 are all critical risk-management elements.
Institutional ILD-management protocols, robust patient education, and well-coordinated collaboration with pulmonary medicine specialists are prerequisites for the safe deployment of T-DXd in the early breast cancer setting.
Regulatory and Clinical Significance
The implications can be organized along three axes.
(1) Rewriting the HER2+ early breast cancer treatment map. HER2+ early breast cancer treatment has improved incrementally over the past decade through the combination of trastuzumab + pertuzumab + taxane neoadjuvantly, and adjuvant T-DM1 (KATHERINE) for residual invasive disease. The new T-DXd approvals advance both: higher pCR rates with neoadjuvant T-DXd, and improved iDFS in the residual-disease adjuvant setting. NCCN, ASCO, and ESMO guideline updates are anticipated in the coming months.
(2) ADCs cross into the curative-intent setting. T-DXd has been approved across HER2+ metastatic breast cancer, HER2-low metastatic breast cancer, HER2+ gastric cancer, and HER2-mutant non-small cell lung cancer. This approval is the first time T-DXd has crossed into early-stage, curative-intent treatment. As such, it is a meaningful precedent for the broader ADC class — opening a clear path for follower programs such as datopotamab deruxtecan (TROP2 ADC) and patritumab deruxtecan (HER3 ADC) to expand into early-disease settings.
(3) ILD management standardization becomes a deployment prerequisite. For T-DXd’s use in early breast cancer to succeed in real-world practice, standardized institutional ILD-management infrastructure is essential. The FDA’s emphasis on patient selection, monitoring protocols, and inter-specialty coordination suggests that center-certification and clinician-training frameworks will shape the pace of safe adoption. Approval status in other jurisdictions is determined separately and should be confirmed via local regulatory authorities.
My Thoughts and Future Outlook
For HER2+ early breast cancer, this is the most consequential treatment-paradigm shift since the KATHERINE trial seven years ago. A pCR rate of approximately 65–70%, and a hazard ratio of about 0.55 for invasive disease-free survival in residual-disease patients — both are clinically meaningful and likely to translate into substantial improvements in long-term outcomes. In a curative-intent setting, an effect of this magnitude has a different kind of impact than the same numbers in metastatic disease.
The flip side is that, in early breast cancer, ILD/pneumonitis carries a different weight. A Grade 5 event in metastatic disease may be acceptable within the overall risk-benefit calculus; in early breast cancer — where many patients face a curable disease — losing a curable patient to treatment toxicity is a categorically heavier loss. Whether an institution has mature ILD-management protocols, whether patient education is thorough, and whether imaging follow-up is consistent — these will determine whether T-DXd’s early-stage promise is realized at the bedside.
The natural next directions include (1) extension of the early-disease indication into HER2-low and HER2-ultralow early breast cancer, (2) optimization of T-DXd treatment duration (14 cycles vs personalized schedules), (3) validation of biomarkers that predict ILD risk, and (4) the broader expansion of ADCs — datopotamab deruxtecan, patritumab deruxtecan — into early-disease settings. This approval is likely to be remembered as the first major milestone in an era where ADCs are part of standard early-disease care.
This article was compiled and summarized by Morningglorysciences based on FDA public materials, the Daiichi Sankyo / AstraZeneca press releases, peer-reviewed publications of the DESTINY-Breast05 and DESTINY-Breast11 trials, and other sources. Treatment decisions should always be made in reference to the original publications, the most recent prescribing information, and local clinical practice guidelines.
Comments